CDMO Curia is to collaborate with Corning’s Advanced-Flow Reactor (AFR) team to expand and accelerate continuous flow development and manufacturing for the chemical and biopharmaceutical industries. This includes installing Corning’s G1 production system (pictured), designed for the continuous industrial production of APIs at Curia’s Albany facility.
Private equity giant Apollo has agreed to acquire the majority of Univar Solutions in an all-cash deal that values the company at about $8.1 billion. There is also an unspecified minority investment from a wholly owned subsidiary of the Abu Dhabi Investment Authority.
Shareholders will receive $36.15/share in cash, which represents a 20.6% premium to the company's undisturbed closing stock price on 22 November 2022 or 33.6% on the volume-weighted average for the 30 trading days ending on that date.
Under a newly signed partnership, AGC Pharma Chemicals and CatSci will combine to offer the former’s expertise in GMP manufacturing from development and manufacturing through to commercial with the latter’s in chemical development, analytical development, crystallisation and solid form, pre-formulation and HPAPI capabilities.
Following two years of construction work, CDMO Siegfried has officially opened its new development centre for drug products at its sites in Barberà del Vallès and El Masnou near Barcelona. About 40 specialist scientists will work there.
The centre features laboratories and pilot capacities, including dedicated facilities for highly potent oral solid dosage forms. Siegfried said that the opening also completes the successful integration of the two sites into its network. It originally acquired them from Novartis in 2020.
Dr Anahita Khanlari, industry marketing director, chemicals, at AspenTech, looks at how digitalisation can expedite the journey towards circularity
Speciality chemicals manufacturer Solenis has agreed to buy cleaning, infection prevention and hygiene giant Diversey. The $4.6 billion all-cash deal should be completed in 2H, subject to approval by Diversey shareholders, and will remove Diversey from public ownership. Both boards have backed it.
An EU-wide project by ECHA’s Enforcement Forum carried out in 2021 has found that most users of substances of commonly controlled very high concern (SVHCs), mainly SMEs, already comply with the authorisation requirement to control risks.
The authorities of all 28 member countries undertook 690 inspections at 516 companies, mostly SVHCs. The most common SVHCs checked were chromium trioxide and strontium chromate, which are used mainly in surface treatment and chrome plating.
